R/M is not recent, but it's commencement has been lingering due partly to US/international regulatory hurdles and management's top priority are it's Shantou and Brunei subsidiaries which are earning 10s of millions in revenue each year. Companies revenues have been slowly declining over the past few years and now it appears like they might tap into the otc entity for financing. That's why I'm here bc if they follow through, this will be much like JBZY/DOLV and perhaps better for the short while AS stays at 100mil